Metabolic disorders such as Diabetes and Obesity are a growing concern and very difficult to address for many people. These conditions can lead to serious health issues and side effects such as cardiovascular disease, peripheral artery disease, atherloscerosis, arthritis and blindness. Drugs can often help with symptoms but the underlying causes and pathologies are not easily treated.

Mitochondrial dysfunction has been studied for these conditions and published peer reviewed research has shown clear linkages to Sirtuins and their activity. Supplementation with NAD+ in animal models has shown significant improvements from many different Universities and Insititutions.

Logo- Weight Loss

Physicians often struggle with these conditions and trying to get patients off to a start on a lifestyle change. There have not been many new options available to support this ‘ jump start” process. Research has shown the mechanism of action can be supported by NAD+ therapy in many animal models and the potential for human interventions holds promise.

Recent Studies

Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases

The below research paper from Harvard University has a broad overview of research on how NAD+ can be used for various metabolic conditions.

Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

This research paper discuss Type 2 diabetes and how NAD+ biosynthesis is crtical to the process as well as supplementation outcomes.

Maternal Nicotinamide Riboside Enhances Postpartum Weight Loss, Juvenile Offspring Development, and Neurogenesis of Adult Offspring

This research shows clear evidence in mice of NAD+ effects on offspring development, brain development and benefits to mothers that supplemented.